Fixed-dose combinations as initial therapy for hypertension: A review of approved agents and a guide to patient selection

Drugs

Volumn 69, Issue 13, 2009, Pages 1761-1776

  Waeber, Bernard ^a,c   Feihl, François ^a   Ruilope, Luis M ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c Division de Physiopathologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS VALSARTAN; ATENOLOL PLUS CHLORTALIDONE; ATENOLOL PLUS NIFEDIPINE; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BENDROFLUMETHIAZIDE PLUS NADOLOL; BISOPROLOL FUMARATE PLUS HYDROCHLOROTHIAZIDE; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; CILAZAPRIL PLUS HYDROCHLOROTHIAZIDE; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; FELODIPINE PLUS METOPROLOL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS METOPROLOL; HYDROCHLOROTHIAZIDE PLUS QUINAPRIL; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; INDAPAMIDE PLUS PERINDOPRIL; NIFEDIPINE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL PLUS VERAPAMIL; TRASITENSIN; UNINDEXED DRUG; VISKALDIX;

CLINICAL TRIAL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG MECHANISM; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; MORBIDITY; MORTALITY; PERIPHERAL EDEMA; POTASSIUM DEFICIENCY; REVIEW; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; HUMANS; HYPERTENSION; PATIENT SELECTION;

EID: 69749123320     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11316710-000000000-00000     Document Type: Review

References (101)

1. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347-60
2. Kearney PM, Whelton M, Reynolds K, et al. Global bur- den of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-23
3. Staessen JA, Wang JG, Thijs L. Cardiovascular preven- tion and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055-76
4. Williams B. Recent hypertension trials: implications and controversies. J Am Coll Cardiol 2005; 45: 813-27
5. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-9
6. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121-3
7. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52
8. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hy-pertens 2007; 25: 1105-87 9. Brunner HR, Menard J, Waeber B, et al. Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. J Hypertens 1990; 8: 3-11 10. Zanchetti A. Angiotensin converting enzyme inhibition in clinical practice: a re-examination of stepped-care: a retrospective and a prospective. J Cardiovasc Pharmacol 1985; 7 Suppl. 1: S126-31
9. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid? J Hum Hypertens 1997; 11: 213-20
10. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10-7
11. Wang YR, Alexander GC, Stafford RS. Outpatient hy- pertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007; 167: 141-7
12. Mancia G, Pessina AC, Trimarco B, et al. Blood pressure control according to new guidelines targets in low- to high-risk hypertensives managed in specialist practice. J Hypertens 2004; 22: 2387-96
13. Banegas JR, Segura J, Ruilope LM, et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 2004; 43: 1338-44
14. Amar J, Vaur L, Perret M, et al. Hypertension in high-risk patients: beware of the under use of effective combination therapy (results of the PRATIK study). J Hypertens 2002; 20: 779-84
15. Ruzicka M, Leenen FH. Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension. Drugs 2001; 61: 943-54
16. White WB. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension. Blood Press Monit 2008; 13: 123-9
17. Struijker-Boudier HA, Ambrosioni E, Holzgreve H, et al. The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbidity-mortality trials? Int J Clin Pract 2007; 61: 1592-602
18. Rosenthal T, Gavras I. Fixed-drug combinations as first- line treatment for hypertension. Prog Cardiovasc Dis 2006; 48: 416-25
19. Waeber B. Treatment strategy to control blood pressure optimally in hypertensive patients. Blood Press 2001; 10: 62-73
20. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed- dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713-9
21. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370: 591-603
22. Dickerson CJE, Hingorani AD, Ashby MJ, et al. Optimi- sation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008-13
23. Law MR, Wald NJ, Morris JK, etal. Value of low dose com- bination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326
24. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus ate-nolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906
25. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59
26. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-16 30. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2977-81
27. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003 (Pubitemid 34286536)
28. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2000; 4: 393-404
29. Mancia G, Messerli F, Bakris G, et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 2007; 50: 299-305
30. Fagard RH, Van den Enden M, Leeman M, et al. Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens 2002; 20: 1297-302
31. Van der Niepen P, Giot C, van de Borne P. Prevalence of isolated uncontrolled systolic blood pressure among treated hypertensive patients in primary care in Belgium: results of the I-inSYST survey. J Hypertens 2008; 26: 2057-63
32. Roux O, Chapellier M, Czernichow S, et al. Determinants of hypertension control in a large French population of treated hypertensive subjects. Blood Press 2006; 15: 6-13
33. Steckelings UM, Stoppelhaar M, Sharma AM, et al. HYDRA: possible determinants of unsatisfactory hypertension control in German primary care patients. Blood Press 2004; 13: 80-8
34. Mancia G, Ambrosioni E, Rosei EA, et al. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens 2005; 23: 1575-81
35. Kjeldsen SE, Naditch-Brule L, Perlini S, et al. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the global cardiometabolic risk profile in patients with hypertension disease survey. J Hypertens 2008; 26: 2064-70
36. European Society of Hypertension-European Society of Cardiology Guidelines Committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53
37. Moser M. Diuretics should continue to be one of the pre- ferred initial therapies in the management of hypertension: the argument for. J Clin Hypertens 2005; 7: 111-6
38. Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J Renin Angiotens Aldoster Sys 2006; 7: 61-3
39. Lithell HO. Effect of antihypertensive drugs on insulin, glu- cose, and lipid metabolism. Diabetes Care 1991; 14: 203-9
40. Perez-Stable E, Caralis PV. Thiazide-induced disturbances in carbohydrate, lipid, and potassium metabolism. Am Heart J 1983; 106: 245-51
41. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-72
42. Berglund G, Andersson O. Hydrochlorothiazide and spir- onolactone alone and in a fixed combination in hypertension. Curr Ther Res 1980; 27: 360-4
43. Bradley HA, Wiysonge CS, Volmink JA, et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006; 24: 2131-41
44. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-53
45. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684-9
46. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3-10
47. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-25
48. Pedersen ME, Cockcroft JR. The latest generation of beta- blockers: new pharmacologic properties. Curr Hypertens Rep 2006; 8: 279-86
49. Naylor WG. The potential for added benefits with beta-blockers and calcium antagonists in treating cardiovascular disorders. Drugs 1988; 35 Suppl. 4: 1-8
50. Waeber B. Position of fixed-dose combinations containing an AT(1)-receptor blocker and a thiazide diuretic. Blood Press 2005; 14: 324-36
51. Waeber B. Combination therapy with ACE inhibitors/ angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther 2003; 1: 43-50
52. Brunner HR, Waeber B, Nussberger J. Renin secretion responsiveness: understanding the efficacy of renin-angiotensin inhibition. Kidney Int 1988; 26: S80-S5
53. Hall D, Motoro R, Littlejohn T, et al. Efficacy and toler- ability of valsartan in combination with hydrochloro-thiazide in essential hypertension. Clin Drug Invest 1998; 16: 203-10
54. MacKay JH, Arcuri KE, Goldberg AI, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension: a double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996; 156: 278-85
55. Kochar M, Guthrie R, Triscari J, et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12: 797-805
56. Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients. J Cardiovasc Pharmacol 1985; 7: S52-S5
57. Malini PL, Strocchi E, Ambrosioni E, et al. Long-term antihypertensive, metabolic and cellular effects of en-alapril. J Hypertens 1984; 2: S101-S5
58. Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20: 369-79
59. Johnson RJ, Kivlighn SD, Kim YG, et al. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999; 33: 225-34
60. Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-9
61. Benz JR, Black HR, Graff A, et al. Valsartan and hydro- chlorothiazide in patients with essential hypertension: a multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12: 861-6
62. McGill JB, Reilly PA. Telmisartan plus hydro- chlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001; 23: 833-50
63. Laurent S. Clinical benefit of very-low-dose perindopril- indapamide combination in hypertension. J Hypertens 2001; 19 Suppl. 4: S9-14
64. Mogensen CE, Viberti G, Halimi S, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes. Pre-terax in albuminuria regression: PREMIER. Hypertension 2003; 41: 1063-71
65. Dahlof B, Gosse P, Gueret P, et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005; 23: 2063-70
66. Patel A, MacMahon S, Chalmers J, et al. Effects of fixed combination of perindopril and indapamide on micro-vascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-40
67. Franklin S, Lapuerta P, Cox D, et al. Initial combination therapy with irbesartan/hydrochlorothiazide for hypertension: an analysis of the relationship between baseline blood pressure and the need for combination therapy. J Clin Hypertens 2007; 9 Suppl. 5: 15-22
68. Black HR, Levy DG, Crikelair N, et al. Predictive age- and dose-related responses to antihypertensive therapy: pooled analysis of two randomized clinical trials of val-sartan alone and combined with hydrochlorothiazide. J Am Soc Hypertens 2008; 2: 476-83
69. Waeber B, Mourad JJ. Targeting systolic blood pressure: the key to controlling combined systolic/diastolic hypertension. Am J Hypertens 2006; 19: 985-6
70. Gojanovic B, Feihl F, Liaudet L, et al. Concomitant cal- cium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension. J Renin Angiotens Aldoster Sys 2008; 9: 1-9
71. Gradman AH, Weir MR, Bakris GL. Newer combination therapies in the management of hypertension: an update. J Clin Hypertens 2008; 10: 398-405
72. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-28
73. Grossman E, Messerli FH. Long-term safety of anti- hypertensive therapy. Prog Cardiovasc Dis 2006; 49: 16-25
74. Luscher TF, Cosentino F. The classification of calcium antagonists and their selection in the treatment of hypertension. Drugs 1998; 55: 509-17
75. Grossman E, Messerli FH. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. Am J Cardiol 1997; 80: 1453-8
76. Bang LM, Chapman TM, Goa KL. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs 2003; 63: 2449-72
77. Kuschnir E, Acuna E, Sevilla D, et al. Treatment of pa- tients with essential hypertension: amlodipine 5mg/bena-zepril 20mg compared with amlodipine 5mg, benazepril 20 mg, and placebo. Clin Ther 1996; 18: 1213-24
78. Karlberg BE, Andrup M, Oden A. Efficacy and safety of a new long-acting drug combination, trandolapril/ verapamil as compared to monotherapy in primary hypertension. Blood Press 2000; 9: 140-5
79. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol 2000; 86: 1182-7
80. Pool J, Kaihlanen P, Lewis G, et al. Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone. J Hum Hypertens 2001; 15: 495-8
81. Jamerson KA, Nwose O, Jean-Louis L, et al. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004; 17: 495-501
82. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and toler-ability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007; 29: 563-80
83. Luft FC, Aronoff GR, Sloan RS, et al. Calcium channel blockade with nitrendipine: effects on sodium home-ostasis, the renin-angiotensin system, and the sympathetic nervous system in humans. Hypertension 1985; 7: 438-42
84. Gennari C, Nami R, Pavese G, et al. Calcium-channel blockade (nitrendipine) in combination with ACE inhibition (captopril) in the treatment of mild to moderate hypertension. Cardiovasc Drug Ther 1989; 3 Suppl. 1: 319-25
85. Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Reports 2002; 4: 479-82
86. Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens 2001; 14: 963-8
87. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007; 21: 220-4
88. Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592-7
89. Cooper-Dehoff R, Cohen JD, Bakris GL, et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol 2006; 98: 890-4
90. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999; 341: 1447-57
91. Grossman E, Messerli FH. Calcium antagonists. Prog Cardiovasc Dis 2004; 47: 34-57
92. Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007; 29: 279-89
93. Rudd P. Clinicians and patients with hypertension: un- settled issues about compliance. Am Heart J 1995; 130: 572-89
94. Waeber B, Brunner HR, Metry JM. Compliance with an- tihypertensive treatment: implications for practice. Blood Press 1997; 6: 326-31
95. Maronde RF, Chan LS, Larsen FJ, et al. Underutilization of antihypertensive drugs and associated hospitalization. Med Care 1989; 27: 1159-66
96. McCombs JS, Nichol MB, Newman CM, et al. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994; 32: 214-26
97. Monane M, Bohn RL, Gurwitz JH, et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens 1997; 10: 697-704
98. Dezii CM. A retrospective study of persistence with single- pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9 Suppl.: 2-6
99. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail 2003; 9: 324-32
100. Giles TD, Berk BC, Black HR, et al. Expanding the defi- nition and classification of hypertension. J Clin Hypertens 2005; 7: 505-12
101. Basile J, Houston M, Ferrario C. Incremental risk-factor reduction improves overall cardiovascular benefit: is it time to abandon the silos? J Clin Hypertens 2006; 8: 686-8